A Novel Composition for Treatment of Diseases by Inducing Mitotic Arrest (10101)
- *Abstract
-
Features and Benefits
- Treats cancers and cancerous tumors by targeting mitotic progression while minimally interacting with microtubules.
- The compounds could be used to treat a wide number of cancers and cancerous tumors.
- The new class of drugs may be less toxic than the current mitotic inhibitors.
*This Technology is available for licensing, further development, or industrial partnering*
Technology
The U of L researchers have developed a novel composition that treats or prevents cancers or cancerous tumors by inducing mitotic arrest or a mitotic catastrophe while minimally interacting with microtubules. This is important because cancer cells can develop resistance to chemotherapeutics that are microtubule disrupters by inactivating the spindle checkpoint. This novel composition induces mitotic arrest by inhibiting the anaphase promoting complex, which is a regulator of mitotic progression or by inhibiting the licensing of pre-replication complexes, thereby, preventing further cell replication and tumor growth.
Markets Addressed
The University of Louisville is seeking a business partner interested in commercializing a novel composition that is capable of treating cancers and cancerous tumors by inhibiting mitotic progression but with minimal or no interaction with microtubules. Cancer is characterized by uncontrolled cellular proliferation. Therefore, chemotherapeutic agents are often compounds that disrupt cell division (eg., mitosis). Some of the current mitotic disrupters in clinical use, such as paclitaxel, target microtubules causing the disruption of mitotic spindle formation. Prolonged mitotic disruption can cause cells to undergo apoptosis. However, tumors can develop resistance to microtubule disrupting drugs by inactivation of the mitotic spindle checkpoint. Thus, there is a need to develop cancer treatments targeting mitotic progression without the development of treatment resistance.
The novel method of inhibiting mitotic progression could be useful in the treatment of cancers resistant to paclitaxel. These new compounds could be administered to the animal or human by any route of administration that provides a therapeutic concentration in the blood. The compounds can be formulated to be released substantially immediately upon administration or any substantially predetermined time or time after administration.
Technology Status
- IP Status: Pending U.S. Patent Application ser. no. 14/114, 352
- Development Status: Pre-clinical
- Fields of Use Available: All commercial fields
- Publications: US 2014/0296242A1
- Country/Region
- USA
